Press Releases

  • Pharmaceutical Companies Expect the Role of Quality Management Teams to Evolve in 2018

    New Report Suggests Pharmaceutical Quality Teams Will Have Performance Oriented Objectives in Addition to Regulatory Compliance Goals

    HAMILTON, N.J., Jan. 15, 2018 - A recent survey sponsored by Sparta Systems and conducted by Pharmaceutical Technology, found that while compliance remains the top objective in 2018 among 73 percent of pharmaceutical executives, performance oriented objectives were nearly as critical for the year ahead.

    The findings of the survey are discussed in a newly issued report entitled 2018 Pharma Quality Outlook: The New Role of Quality Teams. The research cited therein suggests that the role of pharmaceutical quality departments is quickly changing as executives look to enlist the skillset of these teams to better support the business by driving operational efficiency, improving manufacturing performance and accelerating time-to-market, among other objectives.

    "The role of a quality teams is changing for a number of reasons such as global pressure, generic drug competition, and budget cuts," said Brandon Henning, director of product management at Sparta Systems. "These changes are driving companies to be more efficient by looking more closely at how quality impacts their business. We're also seeing regulators take a more data driven approach, so having a quality team and system that supports these demands is going to become crucial for success."

    Alongside key objectives for a successful quality team, the report cites barriers to achieving those objectives as well. Budget and headcount ranked as the top two obstacles in 2018, while compliance and validation was the biggest challenge with existing quality systems.

    Key Findings

    • The biggest challenges to existing quality systems were "ensuring system is compliant with regulations" (60 percent), "usability and scalability" (34 percent) and "training users" (30 percent).  
    • Limited headcount (49 percent), limited budget (44 percent) and data analysis and reporting capabilities (31 percent) were the top obstacles to achieving 2018 objectives.
    • More than half (51 percent) of respondents have defined objectives related to quality data management and analysis.
    • Half (49 percent) of respondents anticipate using quality data to "improve manufacturing performance" in the next 12 to 16 months.

    To access a full copy of the report, please visit:

    Survey Methodology

    The survey of 160 industry executives has been compiled into a full report detailing pharmaceutical companies' goals and objectives for quality control and assurance in 2018.

    About Sparta Systems

    Founded in 1994, Sparta Systems is the world’s premier provider of cloud and on-premise quality management software. We offer the solutions, analytics, and expertise that speed up quality and compliance. Our solutions help to lower risk, increase efficiency, and keep consumers safe while allowing manufacturers, suppliers, and distributors to collaborate in a seamless and integrated environment. Sparta is privately owned and headquartered in Hamilton N.J, with offices across Europe and Asia. We support close to 1 million users across 700+ implementations, in more than 30 countries. Companies in life sciences, consumer products, discrete manufacturing and more, rely on Sparta.


Contact Sparta Systems

(609) 807-5100

Email Contact
© 1995-2021 Sparta Systems, Inc. All Rights Reserved.
© 1995-2021 Sparta Systems, Inc. All Rights Reserved.Sparta Systems Logo